Tolerogenic vaccines for Multiple sclerosis.
Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.
Department of Microbiology and Immunology; Brody School of Medicine; East Carolina University; Greenville, NC USA.
Mark D
MD
Mannie
Alan D
AD
Curtis
D035843:Biomedical Research / Q000639:trends; D004353:Drug Evaluation, Preclinical; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D014612:Vaccines / Q000276:immunology*
D014612:Vaccines
T lymphocytes; autoimmune disease; experimental autoimmune encephalomyelitis; immune; multiple sclerosis; myelin; neuroantigen; therapy; tolerance; vaccine